Viridian Therapeutics Revenue
Biotechnology Research • 
Waltham, Massachusetts, United States • 201-500 Employees
Viridian Therapeutics revenue & valuation
| Annual revenue | $305,000 |
| Revenue per employee | $2,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $976,000 |
| Total funding | $225,000,000 |
Key Contact at Viridian Therapeutics
Company overview
| Headquarters | 203 Crescent St, Building 17, Suite 102B, Waltham, Massachusetts 02453, US |
| Phone number | +16172724600 |
| Website | |
| NAICS | 541714 |
| Founded | 2007 |
| Employees | 201-500 |
| Socials |
Viridian Therapeutics Email Formats
Viridian Therapeutics uses 3 email formats. The most common is {first name}{last name} (e.g., johndoe@viridiantherapeutics.com), used 95.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@viridiantherapeutics.com | 95.7% |
{first initial}{last name} | jdoe@viridiantherapeutics.com | 3.8% |
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Employees by Management Level
Total employees: 201-500
Seniority
Employees
Employees by Department
Viridian Therapeutics has 120 employees across 14 departments.
Departments
Number of employees
Funding Data
Explore Viridian Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
Viridian Therapeutics Tech Stack
Discover the technologies and tools that power Viridian Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Security
Caching
JavaScript libraries
CDN
JavaScript libraries
Miscellaneous
Security
Programming languages
Blogs
Recruitment & staffing
Analytics
SEO
Belgium
United Kingdom
Sweden
Australia
Portugal
GermanyFrequently asked questions
4.8
40,000 users
